31 results about "Necrotic enteritis" patented technology

The present disclosure provides a method of reducing, preventing or treating an intestinal infection, preventing or treating a disease associated with protozoan parasite of the genus Eimeria, inhibiting an oocyst sporulation of a protozoan parasite or preventing a sporozoite invasion or reproduction, preventing or treating coccidiosis, promoting growth performance, controlling, treating and / or preventing necrotic enteritis in a subject, comprising administering to the subject an effective amount of a composition comprising a Crassocephalum rabens (CR), a bioactive extract thereof (CRE), an active ingredient(s) contained in a CR (CR_API) or CRE (CRE_API), a combination of two or more of a CR, a CRE, a CR_API and a CRE_API, or one or more of a-linolenic acid, citric acid, lactic acid, mannitol, palmitic acid, aspartic acid and 1-monomyristin.

The present invention relates to the use of an animal feed additive composition for controlling the growth of undesirable microorganisms, said composition comprising glycerides, vegetable oils, tannins and / or saponins, the glycerol ester is selected from the group consisting of glycerol monopropionate, glycerol dipropionate and glycerol tripropionate, glycerol monobutyrate, glycerol dibutyrate and glycerol tributyrate, glycerol monovalerate, glycerol divalerate and glycerol trivalerate, and mixtures thereof. The invention also relates to the use of the animal feed additive composition for promoting intestinal growth, alleviating or alleviating effects from necrotizing enteritis, modulating intestinal flora and / or as an additive to drinking water.

The invention belongs to the technical field of gene engineering, and particularly relates to recombinant lactobacillus for expressing clostridium perfringens multiple antigens of targeted dendritic cells as well as a construction method and application of the recombinant lactobacillus. The recombinant lactobacillus contains an expression vector for expressing a fusion gene; the fusion gene comprises sequences for coding and expressing a PgsA '-fimA fusion protein, a LysM-Fba fusion protein, an LP1261-NetB fusion protein, a phi54 targeting element and a Pas escape element; a sequence for coding the PgsA '-fimA fusion protein is shown as SEQ ID NO: 1, a sequence for coding the LysM-Fba fusion protein is shown as SEQ ID NO: 2, and a sequence for coding the LP1261-NetB fusion protein is shown as SEQ ID NO: 3. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunocompetence of organisms can be comprehensively enhanced, and the recombinant lactobacillus can be used for preparing oral vaccines for prevention and control of chicken necrotic enteritis.

The invention discloses a feed additive for replacing antibiotics to treat chicken necrotic enteritis and application of the feed additive, and belongs to the technical field of feed. The effective component of the feed additive is the tannin extract from chestnut trees, and animal experiments prove that the tannin extract from chestnut trees can improve the production performance of broiler chickens with necrotic enteritis to a certain extent, improve the intestinal morphology and immune function of the broiler chickens with necrotic enteritis and improve the immunity of the broiler chickens with necrotic enteritis. Therefore, the chestnut tree tannin extract can replace antibiotics and has a good treatment effect on broiler intestinal inflammation caused by clostridium perfringens and coccidiosis.

The application discloses antagonistic Bacillus of Clostridium perfringens type G and application, the Bacillus is Bacillus sonorensis CB-6, and is classified and named as Bacillus sonorensis CB-6, the preservation number is CCTCC NO: M20251373, the preservation date is June 12, 2025, and the preservation unit is China Center for Type Culture Collection, which is located at Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province.The sterile fermentation supernatant of Bacillus sonorensis CB-6 provided by the application has neutral pH value, can inhibit Clostridium perfringens with high activity, the bacteriostatic effect is not dependent on organic acid such as lactic acid, the bacteriostatic effect is significant and stable, can significantly enhance the immunity of laying hens after Clostridium perfringens infection and improve the egg production rate, and solves the problem that laying hens are prone to necrotic enteritis during the egg production period and are not suitable for using antibiotics for prevention and control.

The application discloses application of tree hemp in preparation of a medicine for preventing and / or treating chicken necrotic enteritis, and belongs to the technical field of medicines.The tree hemp can be in the form of medicinal material powder or tree hemp extract.The test result of the application shows that the tree hemp can reduce the mortality of broilers with necrotic enteritis and intestinal lesions of necrotic enteritis, and has a good application prospect in preventing and treating chicken necrotic enteritis.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant lactobacillus plantarum for preventing and controlling chicken necrotic enteritis as well as a preparation method and application of the recombinant lactobacillus plantarum. The invention provides an oral vaccine vector capable of co-expressing various key virulence factor antigens (FimB, NetB, CnaA and FBA) of clostridium perfringens, and by fusing dendritic cell (DC) targeting molecules (nano antibody Phi74), the efficiency of recognizing and taking in the vaccine vector by full-time antigen presenting cells is remarkably improved, so that the immunogenicity is enhanced. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunity of organisms is comprehensively enhanced, and a safe and efficient oral immunization scheme suitable for large-scale breeding is established for treating chicken necrotic enteritis.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

This application discloses the use of soybean saponins in the preparation of drugs or feed additives for the treatment or prevention of necrotic enteritis in chickens. The drugs or additives are soybean saponins or oral liquids, tablets, granules, or powders made with soybean saponins as the active ingredient and added solvents or excipients, with a dosage of 5–50 mg / kg body weight; or soybean saponins can be directly added to the feed at a dosage of 0.01%–0.03% of the total weight of the chicken feed. This application finds that soybean saponins, as drugs or feed additives, have high safety, no toxic side effects, can effectively increase antibody levels in chickens infected with Newcastle disease vaccine, and can alleviate the reduction in chicken production performance, the increase in pro-inflammatory cytokines, and impaired intestinal absorption and barrier function caused by necrotic enteritis infection.

The present invention discloses a Chinese medicine monomer composition, which is mainly composed of citric acid and magnolol. Studies have shown that the drug combination can effectively inhibit the growth of Clostridium perfringens and the formation of biofilm in vitro, wherein the weight ratio of citric acid to magnolol is 50:3, and a synergistic effect can be exerted. At the same time, in vivo experimental results show that the symptoms of necrotic enteritis in yellow-feathered broilers treated with the present invention are significantly alleviated, and improvements are made in terms of weight loss, feed conversion rate, lesion score, inflammatory factors, etc. Therefore, the Chinese medicine monomer composition of the present invention has a good effect on resisting Clostridium perfringens infection and enriches the theory of preventing and controlling Clostridium perfringens infection. The application of the present invention to replace antibiotics to treat necrotic enteritis in chickens can reduce breeding drug residues, create higher economic benefits and ensure human food safety.

This application provides an agent or a composition comprising viable cells or dead cells of the Lactobacillus plantarum strain (International Accession No. NITE BP-03418) as an active ingredient for preventing enteritis or necrotic enteritis, for suppressing inflammation due to enteritis or necrotic enteritis, for suppressing decreased feed conversion efficiency or body weight loss, or for suppressing infection with enteric viruses in a bird (for example, a chicken), or a method that comprises feeding a bird (for example, a chicken) with the agent or the composition.

The present invention relates to a mixture of microorganisms comprising a strain of Lactobacillus reuteri and a strain of Lactobacillus salivarius, its use in preparing an additive or food product for animal use and in preventing or treating necrotic enteritis.

The invention discloses a medicinal and edible traditional Chinese medicine composition for preventing and controlling necrotic enteritis of poultry. The traditional Chinese medicine composition is an extraction process for optimizing an acacia flower extract (taking total flavonoids as a core index), a fructus chebulae extract (taking gallic acid as a core index) and a honeysuckle flower extract (taking chlorogenic acid as a core index), aims at extraction efficiency and active ingredient retention rate, and combines a single factor test and an orthogonal test; the system investigates the influence of the water adding times, the decoction time and the decoction times on the extraction effect. Results show that the traditional Chinese medicine composition with homology of medicine and food composed of the robinia flower extract, the fructus chebulae extract and the honeysuckle flower extract can effectively prevent and control necrotic enteritis of poultry (especially chicken) caused by clostridium perfringens; and the process is stable and feasible and has a good prevention and control effect.

This application discloses the use of *Romebutzella* postbiotics in the preparation of drugs for treating or preventing necrotic enteritis in chickens. The drugs are *Romebutzella* postbiotics or oral liquids, tablets, granules, or powders made with *Romebutzella* postbiotics as the active ingredient, and with the addition of solvents, excipients, or thiophanates. The dosage is 200-800 mg / kg chicken body weight of *Romebutzella* postbiotics; or *Romebutzella* postbiotics or their preparations can be directly added to feed at a concentration of 0.02%-0.08% of the total weight of the chicken feed. This application finds that *Romebutzella* postbiotics, as a drug, have high safety, no toxic side effects, and can effectively alleviate the reduced chicken production performance, increased pro-inflammatory cytokines, and impaired intestinal absorption and barrier function caused by necrotic enteritis.

The invention discloses a phloretin solution for poultry. The phloretin solution is prepared from the following components in parts by mass: 1 part of phloretin, 20 to 35 parts of ethanol serving as a solvent, 2.5 to 7.5 parts of polysorbate 80 serving as a cosolvent, 0.008 to 0.2 part of butylated hydroxytoluene serving as an antioxidant, 0.01 to 0.05 part of phosphoric acid serving as a synergist serving as an antioxidant and 5 to 20 parts of purified water. The preparation method comprises the following steps: dissolving phloretin and butylated hydroxytoluene in ethanol, adding polysorbate 80 and phosphoric acid, adding water to a constant volume, and filtering. The problem that phloretin is easy to separate out when being mixed with water to be administered is solved, the solution stability is high, accurate administration can be achieved, the composition is suitable for preventing necrotic enteritis caused by clostridium welchii in poultry intensive breeding, and the policy requirements of resisting limitation and resisting replacement are met.

The invention discloses application of cannabis sativa in preparation of a medicine for preventing and / or treating chicken necrotic enteritis, and belongs to the technical field of medicine. The cannabis sativa can be in the form of medicinal powder or cannabis sativa extract. Test results show that the Cannabis sativa can reduce the death rate of broilers with necrotic enteritis and intestinal lesions of necrotic enteritis, and has a good application prospect in prevention and treatment of chicken necrotic enteritis diseases.

The present invention relates to: a pharmaceutical composition for preventing or treating necrotic enteritis, the pharmaceutical composition containing TGF-β1 and FGF2 genes or proteins as active ingredients; and a pharmaceutical preparation and a health functional food that contain the pharmaceutical composition. According to the present invention, TGF-β1 and FGF2, which are known to increase the expression of the CFTR gene, can be used as novel agents for inducing intestinal maturation in premature infants, and various digestive complications such as necrotic enteritis and intestinal absorption disorders, which are intractable diseases, can be treated through the same.

The present application belongs to the technical field of genetic engineering, and particularly relates to a recombinant plant lactobacillus for preventing and controlling chicken necrotic enteritis as well as a preparation method and application thereof. The present application provides an oral vaccine carrier capable of co-expressing multiple key virulence factor antigens (FimB, NetB, CnaA, FBA) of Clostridium perfringens, and the efficiency of the vaccine carrier being recognized and taken by professional antigen presenting cells is significantly improved through fusion of dendritic cell (DC) targeting molecules (nanobody Phi74), so as to enhance immunogenicity. Immunization of animals using the recombinant lactobacillus can induce mucosal immunity, cellular immunity and humoral immunity response, and comprehensively enhance the immune ability of the body, thereby establishing a safe, efficient and suitable oral immunization scheme for large-scale breeding for treating chicken necrotic enteritis.

Provided are compositions, feeds, rations, drinking water and methods of use thereof for inducing protective immunity against or preventing Clostridium perfringens infection and / or necrotic enteritis in poultry, optionally as single dose vaccines. The composition comprises live virulent Clostridium perfringens (CP) and a mucosal adjuvant, such as cholera toxin (CT), which is for administered at or after hatch by for example oral delivery. The composition can be used with an immunomodulatory composition administered in ovo before hatching or a boost composition. The composition can be administered as a single dose.

The invention relates to the technical field of feed additives, in particular to a chicken feed additive and application thereof, and the chicken feed additive comprises the following components in parts by weight: 20-50 parts of stevia rebaudiana extract, 30-60 parts of scutellaria baicalensis extract, 10-20 parts of montmorillonite and 20-40 parts of stevia rebaudiana waste residue. The preparation method comprises the following steps: sequentially weighing the stevia rebaudiana extract, the scutellaria baicalensis extract, the montmorillonite and the stevia rebaudiana waste residues in parts by weight, and uniformly stirring and mixing. The feed additive is added into a basal feed in parts by weight, can effectively prevent chicken necrotic enteritis, greatly improves the immunity of broiler chickens, and is more beneficial to the growth of the broiler chickens.

This application provides a recombinant protein, vaccine, and application of Clostridium perfringens type G. Specifically, the recombinant protein of Clostridium perfringens type G has the amino acid sequence set forth in SEQ ID NO. 3. Immunization with this recombinant protein can effectively prevent and treat necrotic enteritis in chickens caused by Clostridium perfringens type G. The vaccine is safe, reliable, and simple to prepare.

The invention discloses a lactobacillus amyloliquefaciens and probiotic microbial inoculum and application of the lactobacillus amyloliquefaciens and probiotic microbial inoculum. The lactobacillus amyloporus is named as lactobacillus amyloporus YI39, and the preservation number of the lactobacillus amyloporus YI39 in the China Center for Type Culture Collection is CCTCC (China Center for Type Culture Collection) NO: M2026104; the nucleotide sequence of 16SrDNA (deoxyribonucleic acid) of the gene is SEQ ID NO. 1. The lactobacillus amyloliquefaciens YI39 provided by the invention is separated from ileum contents of 28-day-old healthy and rapid yellow-feathered broilers, has strong probiotic characteristics, and has relatively good capabilities of inhibiting growth of salmonella pullorum, avian pathogenic escherichia coli, A-type clostridium perfringens and staphylococcus aureus; the body of the broiler chicken can be effectively regulated and controlled, so that the chicken necrotic enteritis caused by clostridium perfringens infection is prevented.

This application discloses a composition for combating necrotizing enteritis in chickens and its application. The active ingredients in the composition, by weight, consist of 5 parts paeonol, 5 parts farnesol, and 1 part soy saponin. This composition can also be formulated into oral liquids, tablets, granules, or powders using paeonol, farnesol, and soy saponin as active ingredients and excipients, with a dosage of 100-1000 mg / kg body weight; or the composition can be directly added to feed at a dosage of 0.1%-1% of the total weight of the chicken feed. The composition formed by paeonol, farnesol, and soy saponin provided in this application, as a drug, has high safety and no toxic side effects. It can effectively inhibit the proliferation of chicken-derived pathogens such as Clostridium perfringens, Salmonella, and Escherichia coli, effectively increase the antibody titer of Newcastle disease vaccine, and alleviate the reduction in chicken production performance, the increase in pro-inflammatory cytokines, and the impairment of intestinal absorption and barrier function caused by coccidiosis and necrotizing enteritis.

The invention discloses a recombinant vector for expressing bacteriophage lyase and a construction method and application of the recombinant vector. The recombinant vector for expressing the bacteriophage lyase is based on a pichia pastoris expression system. The recombinant vector for expressing the bacteriophage lyase comprises a bacteriophage lyase gene, a multiple cloning site, a replication start site, a promoter, a terminator, an alpha-factor signal peptide and a resistance selection marker. According to the recombinant vector of the bacteriophage lyase provided by the invention, the lyase gene is recombined onto the vector, so that the expressed lyase can be used for developing a novel feed additive for preventing necrotic enteritis of poultry directly or after being prepared into a preparation, and a food preservative for controlling clostridium perfringens pollution in meat; or as a therapeutic drug for local or systemic infections.

The present invention relates to a microbial mixture comprising a Lactobacillus reuteri strain and a Lactobacillus salivarius strain and to its use for the preparation of an additive or feed product for animals and for the prevention or treatment of necrotic enteritis.

The invention relates to application of gossypol in preparation of a medicine for treating chicken necrotic enteritis, and belongs to the field of medicine. In-vitro antibacterial activity tests, hemolytic activity inhibition tests, biofilm formation inhibition tests and chicken necrotic enteritis model tests prove that gossypol has a prevention and treatment effect on chicken necrotic enteritis caused by clostridium perfringens infection. The gossypol is preferably gossypol acetate, the minimum inhibitory concentration of the gossypol acetate to clostridium perfringens is 16 mu g / mL, and the minimum bactericidal concentration of the gossypol acetate to clostridium perfringens is 32 mu g / mL. It is found for the first time that gossypol can play a dual anti-infection role by inhibiting the hemolytic activity and biofilm formation of clostridium perfringens. The gossypol provided by the invention can effectively inhibit the growth of clostridium perfringens and the expression of virulence factors of the clostridium perfringens, meanwhile, the intestinal injury and growth performance of sick chickens are improved, and a new technical scheme is provided for green prevention and control of chicken necrotic enteritis.

The invention discloses a nano-particle for preventing chicken necrotic enteritis NE, the nano-particle comprises CeO2 nano-enzyme and maackiain Ma, the CeO2 nano-enzyme and the maackiain Ma form a composite nano-particle Ce-MaNPs through coordination, various active oxygen is efficiently removed through self-cascade reaction, and the nano-particle also has excellent anti-inflammatory ability and intestinal mucosal barrier repair function. The invention further discloses a preparation method and application of the nano-particles for preventing chicken necrotic enteritis NE. Based on the synergistic effect of CeO2 nano enzyme and Ma, Ce-MaNPs is constructed, the drug not only can efficiently remove various active oxygen and relieve intestinal oxidative stress through a self-cascade reaction, but also has excellent anti-inflammatory ability and an intestinal mucosal barrier repair function, so that necrotic enteritis caused by clostridium perfringens infection is effectively prevented.

The invention discloses probiotic bacillus for antagonizing necrotic enteritis of laying hens and application of the probiotic bacillus, the bacillus is Sooraia deserticola bacillus CB-6, the classification name is bacillus sonorensis CB-6, the preservation number is CCTCC NO: M20251373, the preservation date is June 12, 2025, the preservation unit is China Center for Type Culture Collection, the preservation number is CCTCC NO: M20251373, the preservation number is CCTCC NO: M20251373, the preservation number is CCTCC NO: M20251373, the preservation number is CCTCC NO: M20251373, and the preservation number is CCTCC NO: M20251373. The address of the preservation unit is Wuhan University Campus, Wuchang District, Wuchang District, Hubei Province, No. 299. The pH value of a sterile fermentation supernatant of the bacillus sorosa CB-6 provided by the invention is neutral, clostridium perfringens can be inhibited with high activity, the bacteriostatic action does not depend on organic acids such as lactic acid and the like, the bacteriostatic effect is remarkable and stable, the immunity of laying hens infected by the clostridium perfringens can be remarkably enhanced, the laying rate can be increased, and the laying hens can be prevented from being infected by the clostridium perfringens. The problems that the laying hens in the egg producing period are prone to necrotic enteritis and antibiotics are not suitable for prevention and control are solved.

The invention relates to the technical field of biological medicine, and discloses application of maslinic acid or a derivative thereof in preparation of a product for treating clostridium perfringens infection. In-vitro experiments and in-vivo infection models verify that maslinic acid has a good inhibition effect on clostridium perfringens and has a good treatment effect on mammal clostridium perfringens intestinal infection and poultry necrotic enteritis, and a new way and thought are provided for treatment of clostridium perfringens infection; important clinical significance and application value are realized.

This application discloses the use of farnesol in the preparation of drugs or feed additives for the treatment or prevention of necrotic enteritis in chickens. The drugs or feed additives are farnesol or oral liquids, tablets, granules, or powders made with farnesol as the active ingredient and added solvents or excipients, at a dosage of 10–100 mg / kg body weight; or farnesol can be directly added to the feed at a dosage of 0.05%–0.1% of the total weight of the chicken feed. This application finds that farnesol, as a drug or feed additive, has high safety, no toxic side effects, and can effectively alleviate the reduced chicken production performance, increased pro-inflammatory cytokines, and impaired intestinal absorption and barrier function caused by necrotic enteritis.